Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma

Leukemia & Lymphoma
Ellen J KimSean Whittaker

Abstract

Cutaneous T-cell lymphoma (CTCL) is a rare heterogeneous group of non-Hodgkin lymphomas that arises in the skin but can progress to systemic disease (lymph nodes, blood, viscera). Historically, in clinical trials of CTCL there has been little consistency in how responses were defined in each disease "compartment"; some studies only assessed responses in the skin. The histone deacetylase inhibitor romidepsin is approved by the US Food and Drug Administration for the treatment of CTCL in patients who have received at least one prior systemic therapy. Phase II studies that led to approval used rigorous composite end points that incorporated disease assessments in all compartments. The objective of this analysis was to thoroughly examine the activity of romidepsin within each disease compartment in patients with CTCL. Romidepsin was shown to have clinical activity across disease compartments and is suitable for use in patients with CTCL having skin involvement only, erythroderma, lymphadenopathy and/or blood involvement.

References

Feb 5, 1987·The New England Journal of Medicine·R EdelsonG Plewig
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E OlsenJ Nichols
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M DuvicUNKNOWN Bexarotene Worldwide Study Group
Oct 12, 2001·Annals of the New York Academy of Sciences·P Heald
Feb 5, 2005·Blood·Rein WillemzeChris J L M Meijer
Sep 7, 2006·Nature Reviews. Drug Discovery·Jessica E BoldenRicky W Johnstone
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elise A OlsenMadeleine Duvic
Jul 20, 2007·Archives of Dermatology·Vincent D Criscione, Martin A Weinstock
Aug 8, 2008·Future Oncology·Madeleine Duvic, Rakhshandra Talpur
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard L PiekarzSusan E Bates
Feb 6, 2010·Journal of Hematology & Oncology·Jiahuai TanDelong Liu
Feb 9, 2010·Nature Chemical Biology·James E BradnerRalph Mazitschek
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sean J WhittakerYoun H Kim
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elise A OlsenUNKNOWN Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Jan 31, 2012·Journal of the American Academy of Dermatology·Kristen AhernBrian Poligone
Jul 14, 2012·International Journal of Dermatology·Alok Vij, Madeleine Duvic
Aug 2, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rakhshandra TalpurMadeleine Duvic
Sep 6, 2013·JAMA Dermatology·Kaveri KorgavkarMartin Weinstock
Jul 19, 2014·Journal of Psychiatric Practice·David McMahon, Sheldon H Preskorn

❮ Previous
Next ❯

Citations

Sep 18, 2016·Clinical Lymphoma, Myeloma & Leukemia·Francine FossSean Whittaker
Jun 24, 2017·Expert Opinion on Drug Discovery·Piotr Smolewski, Tadeusz Robak
May 7, 2016·Blood·Sean WhittakerH Miles Prince
May 8, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Neha Mehta-ShahYoun H Kim
Sep 3, 2018·American Journal of Clinical Dermatology·Adriana T LopezLarisa Geskin
Nov 28, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Khoan VuWeiyun Z Ai
May 15, 2021·British Journal of Haematology·Tarsheen K SethiNishitha Reddy
Jun 1, 2021·Anais Brasileiros De Dermatologia·José Antonio SanchesJuliana Pereira
Jul 13, 2021·Frontiers in Oncology·Ping Zhang, Mingzhi Zhang
Sep 28, 2021·Current Treatment Options in Oncology·Caitlin M BrumfielAaron R Mangold

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
biopsy

Clinical Trials Mentioned

NCT00106431

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.